Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia 1Hemostatic Disorders 1Hematologic Diseases 1

Interventions

Rituximab 24Cyclophosphamide 10fludarabine phosphate 8Bortezomib 7Lenalidomide 6Tacrolimus 5Mycophenolic Acid 5idelalisib 4ibrutinib 4Peripheral Blood Stem Cell Transplantation 4Antilymphocyte Serum 4tanespimycin 3Whole-Body Irradiation 3Radiotherapy 3Indium 3Dasatinib 3Cyclosporine 3pomalidomide 2ofatumumab 2nelarabine 2ibritumomab tiuxetan 2Vincristine 2Sirolimus 2Radiation 2Prednisone 2Polymerase Chain Reaction 2Methotrexate 2Melphalan 2Magnetic Resonance Spectroscopy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Waldenstrom Macroglobulinemia × epratuzumab × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡